Canine Glaucoma: Diagnosis and Management

This article provides veterinarians and veterinary students with an evidence-based review of glaucoma pathophysiology, breed predisposition, diagnostic techniques, and medical and surgical management options in dogs. The content focuses on practical clinical decisions, diagnostic workflows, and treatment strategies supported by peer-reviewed literature and authoritative veterinary resources.

At a Glance

Pathophysiology of Canine Glaucoma

Glaucoma in dogs results from impaired aqueous humor drainage through the iridocorneal angle and trabecular meshwork, leading to elevated intraocular pressure (IOP) that damages the optic nerve and retina. The normal IOP range in dogs is approximately 10-25 mmHg, with values above 25 mmHg considered suspicious and above 30 mmHg diagnostic for glaucoma. The Merck Veterinary Manual provides comprehensive information on normal ocular physiology and glaucoma pathophysiology [4].

Primary glaucoma occurs when the iridocorneal angle is anatomically abnormal, predisposing the eye to impaired aqueous outflow without concurrent ocular disease. Secondary glaucoma develops when another ocular condition obstructs aqueous outflow, including uveitis, intraocular neoplasia, lens luxation, trauma, or intraocular hemorrhage. The distinction between primary and secondary glaucoma guides treatment decisions and prognostic counseling. The Glaucomas review in Topics in Companion Animal Medicine provides further detail on classification and pathophysiology [6].

The pathophysiology of glaucomatous damage involves both mechanical compression and ischemic injury to retinal ganglion cells and the optic nerve head. Elevated IOP reduces blood flow to the optic nerve, causing axonal degeneration and irreversible vision loss. The rate and severity of damage depend on the magnitude and duration of IOP elevation, with acute elevations causing more rapid vision loss than chronic low-grade elevations. Glaucoma in the dog and cat, published in The Veterinary Clinics of North America Small Animal Practice, describes these mechanisms in detail [7].

Breed Predisposition and Risk Factors

Several dog breeds demonstrate a strong genetic predisposition to primary glaucoma. The Merck Veterinary Manual identifies Cocker Spaniels, Basset Hounds, and Siberian Huskies as breeds with high prevalence of primary glaucoma [4]. Other predisposed breeds include Beagles, Samoyeds, Norwegian Elkhounds, and Wire Fox Terriers. The inheritance pattern in many breeds suggests an autosomal recessive or polygenic mode of transmission.

Breed-specific angle morphology contributes to glaucoma risk. Cocker Spaniels often have a narrow iridocorneal angle with pectinate ligament abnormalities. Basset Hounds frequently exhibit goniodysgenesis, where the pectinate ligament fails to develop normally, leaving a solid sheet of tissue across the angle. Siberian Huskies may have a narrow angle that closes with age or under certain conditions.

Secondary glaucoma can affect any breed but occurs more commonly in breeds predisposed to the underlying condition. For example, breeds prone to lens luxation (Terriers, Border Collies) have higher risk of secondary glaucoma from anterior lens displacement. Breeds with high prevalence of uveitis (Golden Retrievers, Labrador Retrievers) may develop secondary glaucoma from inflammatory obstruction of the drainage angle. The Canine Secondary Glaucomas review in The Veterinary Clinics of North America Small Animal Practice provides detailed information on breed-specific secondary glaucoma risks [9].

Age at onset varies by glaucoma type. Primary glaucoma typically presents in middle-aged to older dogs, with most cases diagnosed between 3 and 7 years of age. Congenital glaucoma, though rare, presents in puppies under 1 year of age. Secondary glaucoma can occur at any age depending on the underlying disease process.

Diagnostic Approach

Tonometry

Tonometry is the essential diagnostic test for glaucoma and should be performed in any dog with suspected ocular disease. The two most common tonometers used in veterinary practice are the applanation tonometer (Tono-Pen) and the rebound tonometer (TonoVet). Both devices provide accurate IOP measurements when used correctly.

The applanation tonometer requires topical anesthesia and measures the force needed to flatten a small area of the cornea. The rebound tonometer uses a small magnetized probe that contacts the cornea and measures the deceleration of the probe as it rebounds. The rebound tonometer does not require topical anesthesia and is generally better tolerated in dogs.

Normal IOP in dogs ranges from 10-25 mmHg. Values consistently above 25 mmHg warrant further investigation, and values above 30 mmHg are diagnostic for glaucoma. The contralateral eye should always be measured for comparison, as unilateral glaucoma may have a normal fellow eye. Asymmetric IOP between eyes is clinically significant even if both values fall within the normal range.

Tonometry should be performed before other diagnostic tests that may alter IOP, such as gonioscopy or ocular ultrasound. The cornea should be examined for edema, which can artifactually lower IOP readings. Multiple measurements should be taken and averaged for accuracy.

Gonioscopy

Gonioscopy allows direct visualization of the iridocorneal angle and assessment of the pectinate ligament and trabecular meshwork. This examination is critical for classifying glaucoma as primary or secondary and for evaluating the contralateral eye in dogs with unilateral glaucoma.

A goniolens is placed on the cornea after topical anesthesia. The lens uses mirrors or prisms to allow visualization of the angle structures that are normally hidden by the corneal limbus. The angle is graded based on the width of the opening and the appearance of the pectinate ligament.

Normal angle anatomy includes a wide open angle with visible pectinate ligament fibers spanning from the iris base to the cornea. In primary glaucoma, the angle may appear narrow, closed, or have abnormal pectinate ligament morphology (goniodysgenesis). Secondary glaucoma typically has a normal angle appearance but with obstruction from inflammatory debris, neoplastic cells, or lens material.

Gonioscopy of the contralateral eye is essential in dogs with unilateral primary glaucoma, as the fellow eye is at high risk for developing glaucoma. The Merck Veterinary Manual recommends gonioscopic evaluation of both eyes in all dogs diagnosed with glaucoma [4].

Ophthalmoscopy

Ophthalmoscopy evaluates the optic nerve head and retina for glaucomatous damage. The optic nerve head should be examined for cupping, pallor, and atrophy. Retinal examination may reveal retinal atrophy, hemorrhage, or detachment.

In acute glaucoma, the optic nerve head may appear normal or slightly hyperemic. In chronic glaucoma, optic nerve cupping becomes evident as the nerve fibers atrophy and the lamina cribrosa bows posteriorly. The optic nerve head may appear pale or white due to loss of blood supply and nerve fiber layer.

Retinal changes in glaucoma include diffuse retinal atrophy, which appears as increased tapetal reflectivity and thinning of the retinal vessels. Retinal hemorrhages may occur in acute glaucoma due to vascular damage from elevated IOP. Retinal detachment can occur secondary to glaucoma or may be the underlying cause of secondary glaucoma.

Ophthalmoscopy should be performed after tonometry and gonioscopy to avoid artifactually altering IOP. Mydriasis may be necessary for complete retinal examination but should be used cautiously in dogs with narrow angles, as pharmacologic dilation can precipitate angle closure.

Ancillary Diagnostic Tests

Ocular ultrasound is indicated when the cornea is edematous or opaque, preventing direct visualization of intraocular structures. Ultrasound can identify lens luxation, intraocular masses, retinal detachment, and vitreal hemorrhage. These findings help differentiate primary from secondary glaucoma and guide treatment decisions.

Systemic diagnostic testing may be indicated for secondary glaucoma when an underlying systemic disease is suspected. Complete blood count, serum biochemistry, and urinalysis can identify inflammatory or neoplastic conditions. Serologic testing for infectious diseases (ehrlichiosis, babesiosis, leishmaniasis) may be appropriate in endemic areas.

Medical Management

Prostaglandin Analogs

Prostaglandin analogs are the most potent topical hypotensive agents available for canine glaucoma. These drugs increase uveoscleral outflow of aqueous humor, effectively lowering IOP. Latanoprost and travoprost are commonly used prostaglandin analogs in veterinary ophthalmology.

Prostaglandin analogs produce rapid IOP reduction, often within 1-2 hours of administration. The effect is dose-dependent and typically lasts 12-24 hours, requiring once or twice daily administration. These drugs are most effective in primary glaucoma where the uveoscleral outflow pathway is intact.

Side effects of prostaglandin analogs include conjunctival hyperemia, miosis, and periocular hair loss. Miosis can be beneficial in primary glaucoma by pulling the iris away from the drainage angle, but it may complicate examination of the posterior segment. Prostaglandin analogs should not be used in eyes with anterior lens luxation, as miosis can trap the lens and worsen the condition.

Beta-Blockers

Beta-blockers reduce IOP by decreasing aqueous humor production at the ciliary body. Timolol is the most commonly used beta-blocker in veterinary ophthalmology. These drugs are less potent than prostaglandin analogs but have a longer duration of action.

Beta-blockers are typically administered twice daily. The IOP-lowering effect is modest compared to prostaglandin analogs, with an average reduction of 15-25% from baseline. Beta-blockers are often used as adjunctive therapy when prostaglandin analogs alone do not achieve adequate IOP control.

Systemic side effects of beta-blockers are rare in dogs but can include bradycardia, hypotension, and bronchoconstriction. These drugs should be used cautiously in dogs with preexisting cardiac or respiratory disease. The ophthalmic formulation is generally well tolerated with minimal local side effects.

Carbonic Anhydrase Inhibitors

Carbonic anhydrase inhibitors reduce IOP by inhibiting the enzyme carbonic anhydrase in the ciliary body, decreasing aqueous humor production. Both topical (dorzolamide, brinzolamide) and systemic (acetazolamide, methazolamide) formulations are available.

Topical carbonic anhydrase inhibitors are administered two to three times daily. They produce a moderate IOP reduction of 15-25% from baseline. These drugs are well tolerated with minimal local side effects, though some dogs may develop conjunctival hyperemia or corneal edema.

Systemic carbonic anhydrase inhibitors are reserved for acute glaucoma when rapid IOP reduction is needed. These drugs produce more potent IOP reduction than topical formulations but have significant systemic side effects. Metabolic acidosis, hypokalemia, gastrointestinal upset, and panting are common adverse effects. Systemic carbonic anhydrase inhibitors should not be used in dogs with renal or hepatic disease.

Osmotic Agents

Osmotic agents rapidly reduce IOP by creating an osmotic gradient that draws fluid from the eye into the bloodstream. Mannitol is the most commonly used osmotic agent for acute glaucoma. It is administered intravenously at a dose that produces rapid IOP reduction within 30-60 minutes.

Osmotic agents are reserved for emergency management of acute glaucoma when IOP is severely elevated and vision is threatened. The effect is temporary, lasting 4-6 hours, and these drugs should not be used as long-term therapy. Contraindications include congestive heart failure, renal disease, and dehydration.

Combination Therapy

Most dogs with glaucoma require combination therapy to achieve adequate IOP control. A typical medical regimen includes a prostaglandin analog, a beta-blocker, and a topical carbonic anhydrase inhibitor. The combination of drugs with different mechanisms of action produces additive IOP reduction.

The choice of medical therapy depends on the type of glaucoma, the severity of IOP elevation, and the presence of concurrent ocular disease. Primary glaucoma often responds well to prostaglandin analogs, while secondary glaucoma may require treatment of the underlying cause in addition to hypotensive therapy.

Medical therapy should be monitored regularly with tonometry to assess efficacy. IOP should be measured at peak and trough drug levels to ensure adequate 24-hour control. If IOP remains elevated despite maximum medical therapy, surgical intervention should be considered.

Surgical Management

Cyclophotocoagulation

Cyclophotocoagulation uses laser energy to destroy portions of the ciliary body, reducing aqueous humor production. Both diode laser and Nd:YAG laser can be used for this procedure. The laser energy is applied transsclerally to the ciliary body, creating focal areas of coagulation necrosis.

The goal of cyclophotocoagulation is to reduce IOP to a level that preserves vision and comfort while minimizing damage to surrounding ocular structures. The procedure is typically performed under general anesthesia and may be combined with other surgical procedures. Surgical Procedures for Glaucoma: What the General Practitioner Needs to Know, published in Topics in Companion Animal Medicine, provides practical guidance on this technique [12].

Success rates for cyclophotocoagulation vary depending on the type of glaucoma and the chronicity of disease. Primary glaucoma has a better prognosis than secondary glaucoma. Multiple treatment sessions may be necessary to achieve adequate IOP control.

Complications of cyclophotocoagulation include postoperative inflammation, hyphema, and phthisis bulbi. Excessive laser energy can cause scleral thinning or perforation. The procedure may need to be repeated if IOP rises again over time.

Drainage Implants

Drainage implants create an artificial pathway for aqueous humor to exit the eye, bypassing the obstructed natural drainage angle. Several types of implants are available, including the Ahmed valve, the Baerveldt implant, and the Molteno implant. These devices consist of a tube that is placed into the anterior chamber and a plate that is secured to the sclera.

The tube allows aqueous humor to flow from the anterior chamber to the plate, where it is absorbed by the surrounding tissues. The implant creates a bleb of fluid under the conjunctiva, which provides resistance to flow and prevents hypotony.

Drainage implants are indicated for glaucoma that is refractory to medical therapy and cyclophotocoagulation. They are particularly useful in secondary glaucoma where the natural drainage angle is irreversibly damaged. Success rates are variable and depend on the underlying cause of glaucoma and the surgical technique. Primary glaucoma in the dog: A review of known therapies and the research into future possibilities Part II: Surgical therapy, published in Vlaams Diergeneeskundig Tijdschrift, reviews outcomes for drainage implant surgery [13].

Complications of drainage implants include tube obstruction, implant extrusion, and postoperative hypotony. The tube may become blocked by fibrin, blood, or iris tissue. The implant may migrate or erode through the conjunctiva. Postoperative inflammation can lead to bleb failure and loss of IOP control.

Enucleation

Enucleation is indicated for blind, painful eyes that do not respond to medical or surgical therapy. The procedure involves removal of the entire globe and is curative for glaucoma-related pain. Enucleation should be considered when the eye is non-visual and the dog is uncomfortable despite medical management.

The decision to enucleate should be made in consultation with the owner, considering the dog's quality of life and the owner's willingness to pursue ongoing medical therapy. Enucleation eliminates the need for topical medications and prevents the development of chronic pain from glaucoma.

Enucleation is a straightforward surgical procedure with a low complication rate. The main risks include hemorrhage, infection, and implant extrusion if a prosthetic implant is placed. Most dogs adapt well to monocular vision and have an excellent quality of life after enucleation.

Other Surgical Options

Cyclocryotherapy uses freezing to destroy ciliary body tissue, similar to cyclophotocoagulation but with a different energy source. This technique is less commonly used due to higher complication rates and less predictable IOP reduction.

Laser trabeculoplasty attempts to improve aqueous outflow by applying laser energy to the trabecular meshwork. This technique is less effective in dogs than in humans due to differences in angle anatomy.

Surgical lens removal may be indicated for secondary glaucoma caused by lens luxation. Removal of the luxated lens can restore aqueous outflow and reduce IOP. This procedure is technically challenging and should be performed by a veterinary ophthalmologist.

Monitoring and Follow-Up

IOP Monitoring

Regular IOP monitoring is essential for all dogs with glaucoma. The frequency of monitoring depends on the severity of disease and the response to therapy. Dogs with acute glaucoma should have IOP measured daily until controlled, then weekly for the first month, and then monthly for the first year.

Chronic glaucoma requires lifelong IOP monitoring. The IOP should be measured at each recheck examination, and the owner should be educated to recognize signs of IOP elevation. Home tonometry is available for motivated owners but requires training and practice.

The target IOP for dogs with glaucoma is below 20 mmHg. IOP consistently above 25 mmHg indicates inadequate control and warrants adjustment of therapy. IOP above 30 mmHg requires immediate intervention to prevent further vision loss.

Vision Assessment

Vision should be assessed at each recheck examination. The menace response, dazzle reflex, and pupillary light reflex provide information about visual function. The menace response is a cortical reflex that requires an intact visual pathway from the eye to the occipital cortex. The dazzle reflex is a subcortical reflex that indicates intact retinal and optic nerve function. The pupillary light reflex tests the afferent pathway from the eye to the midbrain.

Loss of the menace response indicates significant visual impairment, while loss of the dazzle reflex suggests severe retinal or optic nerve damage. Absent pupillary light reflexes indicate advanced glaucoma with poor prognosis for vision.

Objective vision testing can be performed using maze testing or obstacle course testing. These tests assess functional vision in a controlled environment. The owner should be questioned about the dog's ability to navigate familiar and unfamiliar environments.

Owner Education

Owner education is critical for successful glaucoma management. Owners should be instructed on the proper administration of topical medications, including the technique for eye drop instillation and the importance of consistent dosing. The owner should be taught to recognize signs of IOP elevation, including squinting, redness, cloudiness, and behavioral changes.

The owner should understand the prognosis for vision and the goals of therapy. For dogs with primary glaucoma, the contralateral eye is at high risk and should be monitored regularly. The owner should be prepared for the possibility of vision loss and the need for enucleation if the eye becomes blind and painful.

Written instructions should be provided for medication schedules and recheck appointments. The owner should have access to emergency veterinary care if signs of acute glaucoma develop.

Common Failure Patterns

Inadequate IOP Control

The most common cause of treatment failure is inadequate IOP control. This may result from insufficient medication dosing, poor owner compliance, or progression of the underlying disease. IOP should be measured at peak and trough drug levels to ensure adequate 24-hour control.

If IOP remains elevated despite maximum medical therapy, surgical intervention should be considered. Cyclophotocoagulation or drainage implant placement may provide additional IOP reduction. Enucleation should be considered if the eye is blind and painful.

Progression of Underlying Disease

Secondary glaucoma may progress despite adequate IOP control if the underlying disease is not addressed. Uveitis, intraocular neoplasia, and lens luxation require specific treatment in addition to hypotensive therapy. Failure to treat the underlying cause will result in continued damage to the drainage angle and worsening glaucoma.

The underlying disease should be identified and treated aggressively. Uveitis requires anti-inflammatory therapy, intraocular neoplasia may require enucleation or radiation therapy, and lens luxation may require surgical removal. The prognosis for vision depends on the success of treating the underlying cause.

Owner Non-Compliance

Owner non-compliance is a common cause of treatment failure in chronic glaucoma. The need for multiple daily medications and frequent recheck examinations can be burdensome for owners. The cost of medications and veterinary care may also be a barrier to compliance.

The veterinarian should discuss the commitment required for glaucoma management with the owner before initiating therapy. Alternative treatment options, including enucleation, should be discussed if the owner is unable or unwilling to comply with the treatment plan.

Development of Complications

Complications of glaucoma therapy can lead to treatment failure. Prostaglandin analogs can cause conjunctival hyperemia and periocular hair loss, which may be distressing to owners. Beta-blockers can cause systemic side effects in dogs with cardiac or respiratory disease. Carbonic anhydrase inhibitors can cause metabolic acidosis and gastrointestinal upset.

Surgical complications include postoperative inflammation, hyphema, and implant failure. These complications may require additional treatment or revision surgery. The risk of complications should be discussed with the owner before initiating therapy.

Welfare and Safety Considerations

Pain Management

Glaucoma is a painful condition that requires prompt treatment to relieve discomfort. Acute glaucoma causes severe pain due to stretching of the ocular tissues and increased intraocular pressure. Chronic glaucoma may cause less severe but persistent pain.

Pain should be assessed at each recheck examination using behavioral indicators such as squinting, rubbing, and lethargy. Analgesic therapy should be provided as needed, including topical anesthetics for acute pain and systemic analgesics for chronic pain.

Enucleation should be considered for blind, painful eyes that do not respond to medical therapy. Enucleation eliminates pain and improves quality of life. The decision to enucleate should be made in consultation with the owner, considering the dog's comfort and the owner's willingness to pursue ongoing therapy.

Quality of Life Assessment

Quality of life should be assessed regularly in dogs with glaucoma. The owner should be questioned about the dog's activity level, appetite, and behavior. Signs of discomfort, such as rubbing the eye or avoiding bright light, should be noted.

The impact of vision loss on quality of life should be discussed with the owner. Most dogs adapt well to monocular vision, but bilateral vision loss can be challenging. Environmental modifications, such as avoiding furniture rearrangement and using scent markers, can help blind dogs navigate their environment.

The decision to continue medical therapy or pursue enucleation should be based on the dog's quality of life. If the dog is comfortable and the owner is willing to continue therapy, medical management can be maintained. If the dog is uncomfortable or the owner is unable to comply with therapy, enucleation should be considered.

Regulatory Considerations

The use of topical hypotensive medications in dogs is considered extralabel use for most drugs. The veterinarian should inform the owner of the extralabel nature of the therapy and obtain informed consent. The use of systemic carbonic anhydrase inhibitors should be monitored for adverse effects.

The World Organisation for Animal Health provides guidelines for animal health and welfare that apply to the management of glaucoma in dogs [5]. These guidelines emphasize the importance of pain management and quality of life in animals with chronic disease.

Diagnostic and Treatment Decision Framework

Step 1: Initial Assessment

When a dog presents with signs suggestive of glaucoma, the initial assessment should include a complete ophthalmic examination. The examination should begin with observation of the eye for signs of glaucoma, including buphthalmos, corneal edema, conjunctival hyperemia, and mydriasis. The menace response, dazzle reflex, and pupillary light reflex should be assessed to determine visual function.

Tonometry should be performed to measure IOP. If IOP is elevated above 25 mmHg, the diagnosis of glaucoma is confirmed. The contralateral eye should also be measured for comparison.

Step 2: Classification

Once glaucoma is diagnosed, the next step is to classify it as primary or secondary. Gonioscopy is essential for this classification. The iridocorneal angle should be examined for abnormalities of the pectinate ligament and trabecular meshwork.

If the angle appears normal, secondary glaucoma should be suspected. The eye should be examined for signs of uveitis, lens luxation, intraocular neoplasia, or other causes of secondary glaucoma. Ocular ultrasound may be helpful if the cornea is edematous.

Step 3: Treatment Initiation

Treatment should be initiated immediately after diagnosis. For acute glaucoma with IOP above 30 mmHg, emergency therapy is indicated. Osmotic agents may be used for rapid IOP reduction. Topical prostaglandin analogs should be started as first-line therapy.

For chronic glaucoma with IOP between 25-30 mmHg, topical therapy can be initiated without osmotic agents. A prostaglandin analog should be started, and a beta-blocker or carbonic anhydrase inhibitor may be added if needed.

Step 4: Monitoring and Adjustment

IOP should be monitored closely after treatment initiation. The goal is to achieve IOP below 20 mmHg. If IOP remains elevated after 1-2 weeks of therapy, additional medications should be added or the treatment regimen should be adjusted.

If IOP cannot be controlled with maximum medical therapy, surgical intervention should be considered. The type of surgery depends on the type of glaucoma, the visual status of the eye, and the owner's preferences.

Step 5: Long-Term Management

Long-term management includes regular IOP monitoring, vision assessment, and owner education. The frequency of recheck examinations depends on the stability of IOP control. Dogs with well-controlled glaucoma should be rechecked every 3-6 months.

The owner should be educated about the signs of IOP elevation and the importance of consistent medication administration. The owner should also be prepared for the possibility of vision loss and the need for enucleation if the eye becomes blind and painful.

Records and Measurements

Essential Records for Glaucoma Cases

Clinical Signs Documentation

Documentation of clinical signs at each visit allows tracking of disease progression. The following signs should be recorded:

• Ocular pain: squinting, rubbing, blepharospasm
• Corneal changes: edema, vascularization, pigmentation
• Anterior chamber changes: flare, cells, hyphema, hypopyon
• Iris changes: atrophy, synechiae, rubeosis iridis
• Lens changes: cataract, luxation, subluxation
• Vitreal changes: hemorrhage, degeneration
• Retinal changes: atrophy, detachment, hemorrhage
• Optic nerve changes: cupping, pallor, atrophy

Treatment Response Documentation

Response to treatment should be documented at each recheck examination. The following parameters should be assessed:

• IOP reduction from baseline
• Time to achieve target IOP
• Duration of IOP control between doses
• Need for additional medications
• Adverse effects of medications
• Owner compliance with treatment plan

Common Failure Patterns

Failure Pattern 1: Delayed Diagnosis

Delayed diagnosis is a common cause of poor outcomes in canine glaucoma. Owners may not recognize early signs of glaucoma, and the disease may progress to irreversible vision loss before treatment is initiated.

Veterinarians should educate owners about the signs of glaucoma, particularly in predisposed breeds. Routine ophthalmic examinations should be performed in at-risk breeds, including tonometry at annual wellness visits.

Failure Pattern 2: Inadequate IOP Control

Inadequate IOP control is the most common cause of treatment failure. This may result from insufficient medication dosing, poor owner compliance, or progression of the underlying disease.

IOP should be measured at peak and trough drug levels to ensure adequate 24-hour control. If IOP remains elevated despite maximum medical therapy, surgical intervention should be considered.

Failure Pattern 3: Progression of Underlying Disease

Secondary glaucoma may progress despite adequate IOP control if the underlying disease is not addressed. Uveitis, intraocular neoplasia, and lens luxation require specific treatment in addition to hypotensive therapy.

The underlying disease should be identified and treated aggressively. Failure to treat the underlying cause will result in continued damage to the drainage angle and worsening glaucoma.

Failure Pattern 4: Owner Non-Compliance

Owner non-compliance is a common cause of treatment failure in chronic glaucoma. The need for multiple daily medications and frequent recheck examinations can be burdensome for owners.

The veterinarian should discuss the commitment required for glaucoma management with the owner before initiating therapy. Alternative treatment options, including enucleation, should be discussed if the owner is unable or unwilling to comply with the treatment plan.

Failure Pattern 5: Development of Complications

Complications of glaucoma therapy can lead to treatment failure. Prostaglandin analogs can cause conjunctival hyperemia and periocular hair loss. Beta-blockers can cause systemic side effects in dogs with cardiac or respiratory disease. Carbonic anhydrase inhibitors can cause metabolic acidosis and gastrointestinal upset.

Surgical complications include postoperative inflammation, hyphema, and implant failure. These complications may require additional treatment or revision surgery.

Professional Escalation Criteria

Urgent Escalation

The following situations require immediate referral to a veterinary ophthalmologist:

• IOP above 40 mmHg that does not respond to emergency therapy
• Acute glaucoma with vision present but rapidly deteriorating
• Suspected intraocular neoplasia
• Lens luxation with secondary glaucoma
• Glaucoma in a dog with a breed predisposition to primary glaucoma
• Failure of medical therapy to control IOP within 1-2 weeks

Routine Escalation

The following situations warrant referral to a veterinary ophthalmologist on a non-emergency basis:

• Confirmed primary glaucoma in one eye (for evaluation of the contralateral eye)
• Need for gonioscopy or other specialized diagnostic testing
• Consideration of surgical intervention (cyclophotocoagulation, drainage implant)
• Poor response to medical therapy
• Development of complications from medical therapy

When to Consider Enucleation

Enucleation should be considered in the following situations:

• Blind, painful eye that does not respond to medical therapy
• Chronic glaucoma with buphthalmos and corneal degeneration
• Intraocular neoplasia with secondary glaucoma
• Owner unable or unwilling to comply with medical therapy
• Poor quality of life due to glaucoma-related pain

Frequently Asked Questions

What is the difference between primary and secondary glaucoma in dogs?

Primary glaucoma results from an anatomical abnormality of the iridocorneal angle that impairs aqueous humor drainage without concurrent ocular disease. Secondary glaucoma develops when another ocular condition, such as uveitis, intraocular neoplasia, or lens luxation, obstructs the drainage angle. The distinction is important because treatment and prognosis differ between the two types. The Merck Veterinary Manual provides detailed information on both types of glaucoma [4].

Which dog breeds are most predisposed to primary glaucoma?

Cocker Spaniels, Basset Hounds, and Siberian Huskies have the highest prevalence of primary glaucoma. Other predisposed breeds include Beagles, Samoyeds, Norwegian Elkhounds, and Wire Fox Terriers. The Merck Veterinary Manual provides breed-specific information on glaucoma risk [4].

How is intraocular pressure measured in dogs?

Intraocular pressure is measured using tonometry, with the applanation tonometer (Tono-Pen) or rebound tonometer (TonoVet) being the most common devices. The rebound tonometer does not require topical anesthesia and is generally better tolerated. Normal IOP ranges from 10-25 mmHg, with values above 30 mmHg diagnostic for glaucoma.

What are the first-line medical treatments for canine glaucoma?

Prostaglandin analogs, such as latanoprost and travoprost, are the most potent topical hypotensive agents and are often used as first-line therapy. Beta-blockers and carbonic anhydrase inhibitors are used as adjunctive therapy or when prostaglandin analogs are contraindicated. Most dogs require combination therapy for adequate IOP control.

When is surgical intervention indicated for canine glaucoma?

Surgical intervention is indicated when IOP remains elevated despite maximum medical therapy, when the eye is blind and painful, or when the underlying cause of secondary glaucoma requires surgical treatment. Cyclophotocoagulation and drainage implants are options for preserving vision, while enucleation is indicated for blind, painful eyes. Surgical Procedures for Glaucoma: What the General Practitioner Needs to Know provides guidance on surgical decision-making [12].

What is the prognosis for vision in dogs with glaucoma?

The prognosis for vision depends on the type of glaucoma, the chronicity of disease, and the response to therapy. Primary glaucoma has a guarded to poor prognosis without early intervention. Secondary glaucoma prognosis depends on the underlying cause. Early diagnosis and aggressive treatment improve the chances of preserving vision.

How often should a dog with glaucoma be rechecked?

Dogs with acute glaucoma should have IOP measured daily until controlled, then weekly for the first month, and then monthly for the first year. Chronic glaucoma requires lifelong monitoring, with recheck examinations every 3-6 months depending on the stability of IOP control.

What are the signs of glaucoma that owners should recognize?

Owners should be educated to recognize squinting, redness, cloudiness, and behavioral changes such as rubbing the eye or avoiding bright light. Acute glaucoma may cause sudden vision loss, dilated pupil, and corneal edema. Owners should seek emergency veterinary care if these signs develop.

Related Veterinary Guides

• Dog
• Canine Hyperadrenocorticism Cushings Diagnostic Management
• Dog Shedding Management
• How To Skin A Dog
• Arthritis In Dogs Symptoms And Diagnosis

References and Further Reading

• www.merckvetmanual.com
• www.aaha.org
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Glaucomas.. Topics in companion animal medicine, 2015.
• Glaucoma in the dog and cat.. The Veterinary clinics of North America. Small animal practice, 1990.
• Feline glaucomas.. Clinical techniques in small animal practice, 2005.
• Canine Secondary Glaucomas.. The Veterinary clinics of North America. Small animal practice, 2015.
• Glaucoma.. Archives of ophthalmology (Chicago, Ill. : 1960), 1968.
• [Diabetic retinopathy].. Klinische Monatsblatter fur Augenheilkunde, 2021.
• Surgical Procedures for Glaucoma: What the General Practitioner Needs to Know. Topics in Companion Animal Medicine, 2008.
• Primary glaucoma in the dog: A review of known therapies and the research into future possibilities Part II: Surgical therapy. Vlaams Diergeneeskundig Tijdschrift, 2020.
• Glaucoma care in Germany-results of a survey among German ophthalmologists-part 2: treatment. Ophthalmologie, 2022.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.